Medical Library | Shanghai Clinical Innovation Series
Shanghai First People's Hospital, affiliated with Shanghai Jiao Tong University, is a major center for ophthalmology, retinal disease, glaucoma, diabetes-related eye disease, myopia prevention, and kidney transplantation. Its 2025–2026 progress combines national-level eye-disease research with targeted retinal and glaucoma strategies, while the transplant program focuses on difficult immunological matching and complex kidney-care pathways.
This Medical Library review summarizes two representative programs based on the information provided. It also explains how CMCS can help international patients prepare records and communicate with ophthalmology, nephrology, and transplant specialists in Shanghai.
1. Ophthalmology: Comprehensive Care for Vision-Threatening Retinal Disease
Leads: Professors Sun Xiaodong and Zou Haidong
Focus: Vision-threatening retinal disease, retinal detachment, diabetic retinopathy, and myopia prevention.
The ophthalmology center's reported work spans the full pathway from prevention and imaging to complex retinal surgery and treatment of severe neovascular glaucoma.
Key 2025–2026 milestones
- National recognition: The comprehensive diagnostic and treatment strategy for vision-threatening retinal disease received the second prize of the National Science and Technology Progress Award for 2025, announced in 2026.
- Neovascular glaucoma: A randomized clinical trial registration was reported in January 2026 for combined ciliary-body cryotherapy and anti-VEGF treatment in advanced neovascular glaucoma.
Vision-threatening retinal disease is not one condition. Retinal detachment, diabetic retinopathy, retinal vascular occlusion, macular disease, and neovascular glaucoma may require different combinations of injections, laser, cryotherapy, vitrectomy, drainage procedures, and systemic disease control.
Ciliary-body cryotherapy can reduce aqueous-humor production and may be considered in selected advanced glaucoma cases. Anti-VEGF therapy may reduce abnormal vascular growth, but the appropriate combination depends on eye pressure, visual potential, retinal ischemia, inflammation, pain, and the cause of the neovascularization. A registered randomized trial does not mean that the study intervention is already standard care for every patient.
Our related Ophthalmology at Shanghai First People's Hospital guide provides additional background. Patients may also review the retinal disease and cataract article featuring Dr. Sun Xiaodong and the advanced glaucoma treatment guide.
Clinical profile: A national-level eye-disease research platform linking prevention, retinal surgery, diabetic eye care, and advanced glaucoma treatment.
2. Kidney Transplantation: Immunological Preparation for Highly Sensitized Recipients
Lead: Professor Liu Zhihong
Focus: Kidney transplantation in highly sensitized recipients and simultaneous kidney–pancreas transplantation.
Highly sensitized kidney-transplant candidates may have antibodies against many potential donors because of previous transplantation, blood transfusion, pregnancy, infection, or other immune exposure. These antibodies can make it difficult to find a compatible organ and can increase the risk of antibody-mediated rejection.
According to the information provided, the team completed a 2025 “Shanghai First People's Hospital protocol” using Protein A immunoadsorption together with a zero-time biopsy for HLA-sensitized kidney-transplant recipients. Protein A immunoadsorption is designed to remove selected antibodies from the circulation, while a zero-time or implantation biopsy can provide information about the donor kidney at the time of transplantation.
Such a pathway requires careful antibody testing, donor-recipient matching, infection prevention, immunosuppression planning, and post-transplant monitoring. The biopsy result is one part of the decision and does not eliminate the need to monitor kidney function, donor-specific antibodies, rejection, infection, and medication toxicity.
For patients considering kidney transplantation, our related Nephrology and Kidney Transplantation in Shanghai article offers additional background on transplant evaluation and follow-up.
Clinical profile: A transplant program emphasizing differentiated antibody removal and real-time graft assessment for difficult immunological matching.
3. Why These Programs Matter for International Patients
The two programs address different forms of complexity:
- Ophthalmology: preserving vision when retinal ischemia, detachment, diabetes, or abnormal blood-vessel growth has caused severe damage.
- Transplantation: creating a safe pathway for patients whose immune profile makes donor matching difficult.
In both fields, the correct treatment depends on detailed testing. An eye treatment cannot be selected from a diagnosis label alone, and a transplant protocol cannot be selected without antibody profiling, donor information, kidney function, and a full medical history.
4. How CMCS Helps International Patients Communicate with Specialists
For an international patient seeking retinal, glaucoma, diabetic-eye, nephrology, or transplant care in Shanghai, the first step is to match the clinical question with the right specialist team. China Medical Concierge Shanghai (CMCS) is a health management and medical coordination service that helps patients connect with specialist doctors and hospital resources in Shanghai. CMCS is not a hospital and does not independently diagnose or prescribe treatment.
Before an ophthalmology consultation, CMCS can help organize visual acuity records, OCT and fundus photographs, fluorescein or indocyanine-green angiography, visual-field testing, intraocular pressure, previous injections, laser or surgery records, diabetes history, and current symptoms. Before a transplant consultation, CMCS can help organize HLA typing, antibody and donor-specific antibody reports, dialysis history, blood transfusions, pregnancy history, previous transplants, kidney function, pancreas-related diabetes records, and current medication.
CMCS can help patients prepare focused questions such as:
- What is the exact retinal or glaucoma diagnosis, and what is the remaining visual potential?
- Is the proposed treatment standard care, part of a randomized trial, or an investigational combination?
- How will injections, cryotherapy, laser, vitrectomy, pressure control, or surgery be sequenced?
- For transplantation, how highly sensitized is the patient, and what antibody-removal strategy is appropriate?
- What does the zero-time biopsy add, and how will rejection and donor-specific antibodies be monitored afterward?
- What are the major risks, costs, follow-up requirements, and alternatives?
During the consultation, CMCS can assist with appointment coordination, medical interpretation, communication between the patient and the care team, and clarification of the doctor's recommendations. Afterward, a case manager can help organize the proposed next steps, identify additional tests or records, clarify the follow-up schedule, and coordinate further communication with the hospital.
The final treatment decision must be made by the patient and the treating medical team. CMCS does not independently select an eye procedure, injection, transplant protocol, or clinical trial. Its role is to help the patient bring complete information to the right specialist and ensure that evidence, eligibility, risks, alternatives, access, and monitoring are discussed clearly.
To learn more about specialist consultations and treatment coordination in Shanghai, contact CMCS:
Email: contract@medicalsh.com
WhatsApp: Contact CMCS on WhatsApp
Website: medicalsh.com
Conclusion
The Shanghai First People's Hospital programs reviewed here show how specialist medicine is advancing through integrated retinal care, targeted treatment for severe glaucoma, and immunological preparation for complex kidney transplantation.
For patients, the goal is not to pursue every new procedure or device, but to identify the option that fits the diagnosis, visual or kidney function, immune profile, previous treatment, health status, and personal goals. This article was prepared from the team and program information provided for editorial use. Research findings, device status, clinical claims, and treatment access should be confirmed through the hospital, research team, regulatory authorities, and formally published studies. This article is for medical education only and is not individualized medical advice.
0 Kommentare